Entity

Time filter

Source Type


Xiong L.,Peoples Hospital of Gansu Province | Zeng J.,Peoples Hospital of Gansu Province | Yao A.,Tongji University | Tu Q.,Peoples Hospital of Jiujiang County | And 3 more authors.
International Journal of Nanomedicine | Year: 2015

The regeneration of large bone defects is an osteoinductive, osteoconductive, and osteogenic process that often requires a bone graft for support. Limitations associated with naturally autogenic or allogenic bone grafts have demonstrated the need for synthetic substitutes. The present study investigates the feasibility of using novel hollow hydroxyapatite microspheres as an osteoconductive matrix and a carrier for controlled local delivery of bone morphogenetic protein 2 (BMP2), a potent osteogenic inducer of bone regeneration. Hollow hydroxyapatite microspheres (100±25 µm) with a core (60±18 µm) and a mesoporous shell (180±42 m2/g surface area) were prepared by a glass conversion technique and loaded with recombinant human BMP2 (1 µg/mg). There was a gentle burst release of BMP2 from microspheres into the surrounding phosphate-buffered saline in vitro within the initial 48 hours, and continued at a low rate for over 40 days. In comparison with hollow hydroxyapatite microspheres without BMP2 or soluble BMP2 without a carrier, BMP2-loaded hollow hydroxyapatite microspheres had a significantly enhanced capacity to reconstitute radial bone defects in rabbit, as shown by increased serum alkaline phosphatase; quick and complete new bone formation within 12 weeks; and great biomechanical flexural strength. These results indicate that BMP2-loaded hollow hydroxyapatite microspheres could be a potential new option for bone graft substitutes in bone regeneration. © 2015 Xiong et al. Source


Zhang C.-D.,Guangxi Medical University | Zhang C.-D.,Affiliated Hospital of Youjiang Medical College for Nationalities | Li H.-T.,Guangxi Medical University | Liu K.,The Third Hospital of Nanchang City | And 8 more authors.
Asian Pacific Journal of Cancer Prevention | Year: 2014

Background: Despite evidence suggesting roles for caspase-8 (CASP8) -652 6N del and D302H polymorphisms in prostate cancer (PCa), the association of these polymorphisms with PCa risk remains inconclusive. Therefore, a meta-analysis was performed to more precisely estimate the association of CASP8 -652 6N del and D302H polymorphisms with PCa susceptibility. Materials and Methods: A comprehensive literature search was conducted to identify all case-control studies of CASP8 D302H and -652 6N del polymorphisms and PCa risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association and the precision of the estimate, respectively. Results: Nine -625 6N del studies and 4 D302H studies were included. CASP8 -652 6N del and D302H polymorphisms were not significantly associated with PCa risk in the overall analyses. However, in the subgroup analysis stratified by ethnicity, -625 6N del was significantly associated with PCa risk in the East Asian and Indian populations under the recessive model. Furthermore, the subgroup analysis strongly suggested that D302H was associated with lower PCa risk in the Non-Indian population under the dominant model. Conclusions: In our meta-analysis, ethnic-specific differences were evident in the association of CASP8 -625 6N del and D302H polymorphisms with PCa risk. Source


Liu Y.,The Third Hospital of Nanchang City | Qiu W.,The Third Hospital of Nanchang City | Tu J.,The Third Hospital of Nanchang City
Asian Pacific Journal of Cancer Prevention | Year: 2011

Objective: To investigate the clinical features, molecular phenotypes and clinical prognosis of breast cancer patients with type-2 diabetes mellitus, thereby providing a basis for individualized therapy of breast cancer. Methods: 105 breast cancer patients with type-2 diabetes mellitus (DM) presenting from January 2005 to December 2010 were enrolled in this study. 200 breast cancer non-diabetic patients in the same period were randomly selected as the control group. The clinical data of DM group and control group were retrospectively analyzed. The SPSS12.0 software was used for statistics and survival analysis. Results: The mean age of the patients in DM group were of 57.2±11.8 years, which was older compared with the control group. The percentage of postmenopausal patients was 71.4% and the ratio of grade II+III was 98.8%, which was higher than the control group. The neoadjuvant chemotherapy response rate of DM group was 67.5%, which was lower than control group. The patients in DM group had later clinical stage and more lymph metastasis. The proportion of advanced breast cancer was 68.57% and the ratio of lymph node metastasis was 66.01%. All the difference was significant (P<0.05). But there was no significant difference in tumor size and molecular phenotype between the diabetic group with breast cancer and the control group. Disease-free survival and overall survival rates of DM group were 80.2% and 84.2%, which were worse than those in the control group. All the difference was significant (P<0.05). After excluding the patients with other causes of death, results of overall survival still showed worse in DM group, but the difference was not statistically significant(P>0.05). Serum insulin at fasting and two hours postprandial were higher than normal value in DM group, but serum insulin levels in the control group changed in the normal range. Conclusion: There were older patients, with a higher proportion of high pathological grade, more lymph node metastasis, later clinical stages in the diabetic group with breast cancer. Breast cancer patients with type-2 diabetes mellitus were at risk of a poor prognosis. Hyperinsulinemia may be the real cause of poor prognosis in breast cancer patients with type-2 diabetes. Source

Discover hidden collaborations